Apexigen Announces Review of Strategic Alternatives and Restructuring
SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative...
Year: 2023
UpHealth Announces Strategic Sale of Innovations Group Incorporated to Belmar Pharma Solutions for Approximately $56 Million in Gross Proceeds
~ Represents a Substantial Milestone in UpHealth’s Focus on Further Integration of its Telehealth, Integrated Care and Behavioral Health Businesses...
Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
Test Delivers Lab-Quality Performance with Results in 30 Minutes or Less – The First At-Home Test to Ever Include Flu...
Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023
MORRISTOWN, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative...
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer Lyra Therapeutics CTO John Bishop, Ph.D. WATERTOWN, Mass.,...
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class...
Financière de Tubize – Annual Report 2022
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: eric.nys@financiere-tubize.be Annual Report 2022 Regulated information25 February 2023...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,...
Regional Health Properties, Inc. Regains Compliance with NYSE American Continued Listing Standards
ATLANTA, GA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “we,” “us” or “our”) (NYSE American:...
IRADIMED CORPORATION Issues Urgent Medical Device Correction
Letter Notifying Customers of Potential Issues with MRidium 1057 MRI Syringe Adapter SetWINTER SPRINGS, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE)...
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on...
Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology...
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin, 1 January – 31 December 2022 (unaudited)
BBS-Bioactive Bone Substitutes Plc, Financial Statements Bulletin, 24 February 2023 at 3.00 p.m. BBS advances towards the CE marking of...
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany BASKING RIDGE, NJ,...
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving...
Decentralized Trials & Research Alliance Release Best Practices Rubric to Provide Framework to Evaluate DCT Processes
Global cross-industry collaboration continues sharing outputs from portfolio of initiatives SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The Decentralized...
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039WARRINGTON, Pa., Feb. 24, 2023...